Home » LUNDBECK REPORTS CIPRALEX STUDY RESULTS
LUNDBECK REPORTS CIPRALEX STUDY RESULTS
H. Lundbeck has announced that two Phase III studies of its Cipralex antidepressant show that the drug is effective and well-tolerated in treatment of patients suffering from obsessive-compulsive disorder.
Cipralex is currently approved for the treatment of depression, panic disorder, social anxiety disorder, and generalized anxiety disorder.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
25Apr
-
07May
-
14May
-
30May